What does the Bristol Myers Squibb–Hengrui deal reveal about China's role in global pharmaceutical R&D?

The $600 million up-front payment plus $175 million in annual payments over two years for joint development of drug candidates—under which BMS gains worldwide commercial rights and Hengrui retains rights in China—demonstrates that Chinese firms like Jiangsu Hengrui Pharmaceuticals are now key sources of novel, licensable therapeutic molecules for major US pharmaceutical companies, signaling China's ascent as a global hub for pharmaceutical innovation rather than just generic manufacturing.

How did Jiangsu Hengrui Pharmaceuticals evolve from a domestic generic drugmaker into an international R&D partner?

Founded in 1970 to produce generic medicines for the local market, Hengrui followed a strategic transition from copycat drug manufacturing to developing novel, patent-protected pharmaceuticals—a shift emblematic of how Chinese pharma companies have moved into the high-value, innovation-driven segment of the industry.

China Outpaces US in Pharmaceutical R&D and Innovation

Jul 29, 2026

Bristol Myers Squibb paid Jiangsu Hengrui Pharmaceuticals $600 million upfront to license therapeutic molecules, highlighting China's shift from generic to novel drug innovation.

cen

2026-07-29

China Outpaces US in Pharmaceutical R&D and Innovation

China Outpaces US in Pharmaceutical R&D and Innovation

FAQ